All Kaerus Bioscience articles
-
NewsServier acquires treatment for autism genetic cause Fragile X syndrome
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.